top of page
INSIGHTS
We equip our clients with actionable insights drawn from meticulous analysis of data, firsthand experience, and comprehensive interviews. The contextual evidence we provide enables quick, confident decision-making. We're known for our unique ability to view opportunities and challenges from both the company's and the customer's vantage points, offering a nuanced perspective that can't be found anywhere else.
Filter
Shortages and Slowdowns: How Pharmaceutical Tariffs Threaten Supply and Innovation
The Trump administration is doubling down on its promise of pharmaceutical tariffs, designed to re-shore manufacturing and protect strategic interests. What would it mean for biopharma? More importantly, what would it mean for patients? In this article, we summarize existing perspectives and dive into some less-explored topics, such as clinical trial execution, budget management, and early-stage investment.
Liam Boyd
Apr 15, 20254 min read
Charting "The Next Frontier" in Medical Device Commercialization: Spinnaker's Perspective in MedTech Strategist
To thrive in today’s evolving healthcare market landscape, medical device companies must take a cohesive, strategic approach to address the complexities and opportunities of the current environment. Success will hinge on aligning commercial models with customer priorities, reducing inefficiencies, and leveraging technology to drive smarter decisions. By Jeremy Cohen, Spinnaker Life Sciences Strategy Consulting.
Jeremy Cohen
Apr 10, 20251 min read
Expanding GLP-1s: is Neurology the Next Frontier?
GLP-1 therapies transformed obesity & diabetes care and are now being explored for potential breakthroughs in neurological diseases.
Federico Somaini
Apr 2, 20255 min read
Financial Planning and Analysis Strategies in the Life Sciences
Strategic FP&A is vital for emerging life sciences companies facing long R&D cycles and capital constraints. By aligning financial insights with scientific priorities, FP&A enables smarter capital allocation, scenario planning, and investor confidence. Robust FP&A functions drive data-driven decisions, extend runway, and enhance operational discipline—empowering biotech and pharma leaders to balance innovation with financial sustainability and accelerate progress toward comme
Dane Callow
Mar 26, 20252 min read
Maximizing Financial Performance Through Strategic FP&A Outsourcing: A Competitive Edge for Emerging Life Sciences Companies
Outsourcing FP&A can optimize finances, accelerate R&D, and enhance investor confidence, for biotech and pharma firms under $500M cap
Dane Callow
Mar 25, 20259 min read
A Snapshot into AI in Drug Discovery: Progress, Hurdles, and the Path Forward
AI promised to revolutionize drug discovery, pledging faster development, reduced costs, and lowered risks. However, the reality has proven far more nuanced than initially expected. While AI is undoubtably making innovative strides in the industry, its true impact requires a closer look: where has AI succeeded, and where does it still fall short? Table of Contents The Current State of AI in Drug Discovery Current Successes Missed Marks and Growth Points A Look Ahead; Braci
Daniel Yuan
Mar 21, 20255 min read
bottom of page